Savara Q2 loss widens as operating expenses rise
SVRA•Cash position and regulatory outlook
Savara ended the second quarter with $173 million in cash and short-term investments.
The company expects an FDA decision on MOLBREEVI by Nov. 22, 2026. It also anticipates EMA and MHRA regulatory decisions in Q1 2027 and Q4 2026, respectively. Savara said its focus is on a potential U.S. launch of MOLBREEVI, supported by its current cash position.
Key quarterly figures and analyst view
| Metric | Actual |
|---|---|
| Q2 loss per share | $0.16 |
| Q2 net loss | $40.23 million |
| Q2 income from operations | -$40.97 million |
| Q2 operating expenses | $40.97 million |
The current average analyst rating on the shares is buy, with 8 recommendations rated strong buy or buy, and no hold, sell or strong sell ratings. The median 12-month price target is $10.25, about 78.9% above Savara's Aug. 10 closing price of $5.73.
